Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVX-CoV2540
- Development stage
- Phase 3
- Lead developer
- Novavax
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
NVX-CoV2540 is a recombinant protein-based COVID-19 vaccine developed by Novavax targeting the Omicron BA.5 subvariant of SARS-CoV-2. It consists of a recombinant spike (S) protein nanoparticle formulated with the Matrix-M adjuvant to enhance immunogenicity. The vaccine is designed to stimulate robust neutralizing antibody responses against the Omicron BA.5 variant, and clinical studies have shown it induces higher neutralizing titers for this subvariant compared to earlier Novavax vaccines and bivalent formulations[4][5][6]. The mechanism of action involves immunostimulation through presentation of the spike protein antigen, leading to an enhanced immune response.
- Other names
- Omicron BA.5 SARS-CoV-2 rS /Matrix-M Adjuvant
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on NVX-CoV2540.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVX-CoV2540.